Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274750 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT05274750 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 276 participants.
The verdict
NCT05274750, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
Interventions
- DRUG Placebo
- BIOLOGICAL Depemokimab (GSK3511294)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05274750
The ClinicalTrials.gov registry entry for NCT05274750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05274750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05274750 about?
NCT05274750 is a clinical study titled "Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps". This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
What is the current status of trial NCT05274750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2022-04-22. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT05274750?
The interventions under investigation include: Placebo (DRUG), Depemokimab (GSK3511294) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05274750?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.